Difference between revisions of "Part:BBa K3111011:Design"

(→‎References)
(→‎References)
Line 26: Line 26:
 
[5] Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov Today. 1 de agosto de 2008;13(15):695-701.
 
[5] Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov Today. 1 de agosto de 2008;13(15):695-701.
  
−
[8] Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol. octubre de 2009;393(3):598-607.
+
[6] Using Mimics to Get Around Antibodies’ Limitations [Internet]. The Scientist Magazine®. [cited on 26th June 2019]. Available at: https://www.the-scientist.com/lab-tools/using-mimics-to-get-around-antibodies-limitations-64264
  
−
[9] Using Mimics to Get Around Antibodies’ Limitations [Internet]. The Scientist Magazine®. [cited on 26th June 2019]. Available at: https://www.the-scientist.com/lab-tools/using-mimics-to-get-around-antibodies-limitations-64264
+
[7] Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol. octubre de 2009;393(3):598-607.
  
−
[10] DARPins: an eye-opening new biologic therapy [Internet]. [cited on 26th June 2019]. Available at: https://www.drugdevelopment-technology.com/comment/darpins-eye-opening-new-biologic-therapy/
+
[8] DARPins: an eye-opening new biologic therapy [Internet]. [cited on 26th June 2019]. Available at: https://www.drugdevelopment-technology.com/comment/darpins-eye-opening-new-biologic-therapy/
  
−
[11] Siegler E, Li S, Kim YJ, Wang P. Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells. Hum Gene Ther [Internet]. 2017 Sep 1 [cited 2019 Sep 14];28(9):726–36.  
+
[9] Siegler E, Li S, Kim YJ, Wang P. Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells. Hum Gene Ther [Internet]. 2017 Sep 1 [cited 2019 Sep 14];28(9):726–36.  
  
−
[12] Steiner D, Forrer P, Plückthun A. Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display. J Mol Biol [Internet]. 2008 Oct 24 [cited 2019 Sep 14];382(5):1211–27.
+
[10] Steiner D, Forrer P, Plückthun A. Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display. J Mol Biol [Internet]. 2008 Oct 24 [cited 2019 Sep 14];382(5):1211–27.

Revision as of 23:47, 13 October 2019


DARPin929


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

Start codon and stop codons removed for fusion onto the C or N terminus. The sequence was then optimised for lowered repeat count.

Source

DARPin929 is a de novo protein created using error-prone PCR and ribosome display by A. Plückthun in 2008 (8). Sequence was taken from 4HRL on RCSB Protein Data Bank. Synthesised by IDT.

References

[1] Plückthun A. Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy. Annual Review of Pharmacology and Toxicology. 2015;55(1):489-511.

[2] Janeway CA, Medzhitov R. Innate Immune Recognition. Annu Rev Immunol. 1 de abril de 2002;20(1):197-216.

[3] Forrer P, Stumpp MT, Binz HK, Plückthun A. A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett. 27 de marzo de 2003;539(1):2-6.

[4] Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A. Designing Repeat Proteins: Well-expressed, Soluble and Stable Proteins from Combinatorial Libraries of Consensus Ankyrin Repeat Proteins. J Mol Biol. 12 de septiembre de 2003;332(2):489-503.

[5] Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov Today. 1 de agosto de 2008;13(15):695-701.

[6] Using Mimics to Get Around Antibodies’ Limitations [Internet]. The Scientist Magazine®. [cited on 26th June 2019]. Available at: https://www.the-scientist.com/lab-tools/using-mimics-to-get-around-antibodies-limitations-64264

[7] Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol. octubre de 2009;393(3):598-607.

[8] DARPins: an eye-opening new biologic therapy [Internet]. [cited on 26th June 2019]. Available at: https://www.drugdevelopment-technology.com/comment/darpins-eye-opening-new-biologic-therapy/

[9] Siegler E, Li S, Kim YJ, Wang P. Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells. Hum Gene Ther [Internet]. 2017 Sep 1 [cited 2019 Sep 14];28(9):726–36.

[10] Steiner D, Forrer P, Plückthun A. Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display. J Mol Biol [Internet]. 2008 Oct 24 [cited 2019 Sep 14];382(5):1211–27.